Verrica Pharmaceuticals
Market cap $53.9M 17.2M shares (10-Q, Nov 5, 2026) × $3.14 close Nov 17, 2026
Most recent annual filing: 2026-03-11
- YCANTH commercial units corporate updateNov 2026YCANTH commercial units corporate update, Nov 2026, routine
- YCANTH (VP-102) common warts toplinemid-2027YCANTH (VP-102) common warts topline, mid-2027, thesis-defining
- Verrica financingJun 2027Verrica financing, Jun 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
YCANTH
cantharidin · VP-102ruxotemitide
VP-315Discontinued (2)
- YCANTH — External Genital Warts · Paused for funding, not for a result: "we have paused the development of VP-102 for the treatment of external genital warts and VP-103 for the treatment of plantar warts due to our cash position" (10-K, 2026-03-11). The 10-K's pipeline graphic lists both under "Potential Future Development Opportunities", separately from "Active Product Candidates". Flips back if funding resumes.
- cantharidin — Plantar Warts · Paused for funding, not for a result: "we have paused the development of VP-102 for the treatment of external genital warts and VP-103 for the treatment of plantar warts due to our cash position" (10-K, 2026-03-11). The 10-K's pipeline graphic lists both under "Potential Future Development Opportunities", separately from "Active Product Candidates". Flips back if funding resumes.
Capital (as filed)
- Cash
- $14.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$9.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $14.4M cash, runway into the fourth quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-13 UPDATE: Verrica Pharmaceuticals (VRCA) - The Price Turned, the Units Blinked 🔒 Paid
- 2026-10-23 UPDATE: Verrica Pharmaceuticals (VRCA) - The Delayed Draw Unlocks 🔒 Paid
- 2026-08-27 UPDATE: Verrica Pharmaceuticals (VRCA) - The Catalyst Moved to the Money 🔒 Paid
- 2026-08-24 Verrica Pharmaceuticals (VRCA) — Scientific Deep Dive for YCANTH, VP-102 in Common Warts, and VP-315 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Verrica Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-24 Watch Verrica Pharmaceuticals (VRCA) — Scientific Deep Dive for YCANTH, VP-102 in Common Warts, and VP-315 Going-concern balance sheet cannot reach its own mid-2027 catalyst on committed capital, and the Chairman holds a first lien plus a 16% IRR catch-up that triggers on commercial success, keeping the stock on the sidelines until the delayed draw unlocks or a signed partnership funds the gap.
- 2026-08-27 Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Catalyst Moved to the Money COVE-2 enrollment completion pulled the topline into Q1 2027, inside the committed-capital window, eliminating the timing mismatch that was the load-bearing beam of the bear case and warranting a small starter position sized for total loss.
- 2026-10-23 Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Delayed Draw Unlocks The full $27.5M facility is now available after Verrica met the lender's milestones, funding both COVE pivotal readouts without a dilutive raise, satisfying the first of the two conditions set in the deep dive for moving off the sidelines.
- 2026-11-13 Speculative buy speculative UPDATE: Verrica Pharmaceuticals (VRCA) - The Price Turned, the Units Blinked Q3 per-applicator revenue rebounded to ~$298, burn held near $9.3M/quarter, and the delayed draw is unlocked, passing all three hard-review checks, though a sequential unit dip and shortened runway guidance are flagged as risks to monitor into COVE-2.
- Long call · opened Aug 28, 2026 at $5.69 · -44.8% vs XBI -10.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (5 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Top-line data is anticipated in the first quarter of 2027 for COVE-2, with the remaining top-line data from our Program expected to be available in mid-2027.”
matched to YCANTH (VP-102) common warts · topline data
-
-
-
“We have also enrolled more than 50% of the current patient target in the second pivotal trial, and we expect topline data from these trials in the first quarter of 2027 and mid-2027, respectively.”
matched to YCANTH (VP-102) common warts · topline data
-
-
-
“Top-line data from our Program is expected in mid-2027.”
matched to YCANTH (VP-102) common warts · topline data
-
-
-
“Topline data from our global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well.”
matched to Verrica (financing) · financing / matched to YCANTH (VP-102) common warts · topline data
-
-
-
“Topline data from our global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well.”
matched to Verrica (financing) · financing
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 202610-QQuarterly report
- Nov 12, 2026ReleaseVerrica Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings after the close: record YCANTH revenue of $5.7M with improving gross-to-net — the price-erosion bear case may be turning — but units dipped sequentially for the first time, and VP-315 just found a new target in Gorlin syndrome that could unlock an orphan pathway nobody was pricing in.
- Nov 10, 2026ReleaseVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
- Nov 5, 2026ReleaseVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
- Oct 22, 2026ReleaseVerrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility→ BD updateThe redacted milestone gate that kept the $15M delayed draw locked — and kept VRCA on a watch list — just cleared. The full $27.5M facility is now available, funding both Phase 3 wart readouts and removing the central financing uncertainty the bear case was built on.
- Sep 30, 2026ReleaseVerrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology ConferencesBD extracted 2 program updates from this document → VRCA pipeline
- Sep 10, 2026ReleaseVerrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
- Sep 8, 2026ReleaseVerrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 27, 2026ReleaseVerrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027→ BD updateCOVE-2 enrollment is complete and topline data is now expected Q1 2027 — roughly a quarter earlier than the mid-2027 guide — while a blinded interim power analysis confirmed no additional patients are needed, a subtle but important data-quality signal. The pull-forward compresses the funding gap in the company's favor but doesn't close it.BD extracted 1 program update from this document → VRCA pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 9, 20268-KCurrent report: officer / director change, shareholder vote
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 20, 2026DEFA14AProxy soliciting material
- Apr 20, 2026DEF 14AProxy statement
- Mar 11, 20268-KCurrent report: results of operations · EX-99.1
- Mar 11, 202610-KAnnual report
4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- May 12, 2026S-8Employee plan registration
- Apr 20, 2026ARSAnnual report to shareholders